JP2020059711A - 自閉症を治療するための医薬組成物 - Google Patents
自閉症を治療するための医薬組成物 Download PDFInfo
- Publication number
- JP2020059711A JP2020059711A JP2019191270A JP2019191270A JP2020059711A JP 2020059711 A JP2020059711 A JP 2020059711A JP 2019191270 A JP2019191270 A JP 2019191270A JP 2019191270 A JP2019191270 A JP 2019191270A JP 2020059711 A JP2020059711 A JP 2020059711A
- Authority
- JP
- Japan
- Prior art keywords
- substance capable
- asd
- patients
- pharmaceutical composition
- ibudilast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
・細胞内cAMPレベルを上昇させることができる物質、及び、
・細胞内カルシウム濃度を調節することができる物質。
・細胞内cAMPレベルを上昇させることができる物質、及び、
・細胞内カルシウム濃度を調節することができる物質。
イブジラストは、一日の総用量が約1〜150mgの範囲、好ましくは約5〜80mgの範囲、より好ましくは約15〜50mgの範囲で、1回分、2回分又は3回分に分けて患者に投与されてもよい。イブジラストは、1、5、10、15、20、25、30、35、40、45若しくは50mgのイブジラスト又はその薬学的に許容可能な塩を含む剤形を用いて、1日1回、2回又は3回患者に経口投与されてもよい。
・患者がASD表現型1に罹患しているかどうかを判定すること、及び、
・患者がASD表現型1に罹患している場合、患者に治療有効量の医薬組成物を投与すること
を含んでおり、
患者がASD表現型1に罹患しているかどうかを判定することは、
・Nrf2−活性化剤を用いた負荷試験を患者に受けさせること、
・増殖関連経路の発現が高まる臨床徴候を確認すること、
・Nrf2の上方制御を確認すること、又は
・プロテインキナーゼAの低い血中レベルを確認すること
のうち少なくとも1つを含んでおり、
患者が、スルホラファン等のNrf2活性化剤を用いた負荷試験におけるネガティブな行動応答、増殖関連経路の発現が高まる臨床徴候、Nrf2の上方制御又はプロテインキナーゼAの低い血中レベルのうち少なくとも1つを示す場合には、患者がASD表現型1に罹患していると判定する。
・少なくとも1つの必須特性:
・対照集団に対して拡大した頭のサイズ。24ヶ月時点にて平均頭囲より大きい標準偏差及び/又は外形的な巨頭症(頭囲が一般集団の97%より大きい)の少なくとも1つを特徴とする。
及び/又は
・自閉症の中核症状又は付随症状の周期的な悪化。感染事象の期間、乳歯の喪失、外傷後傷害、内因性及び外因性の温度変化によって増強される。
並びに、
・以下の20の特徴の少なくとも2つ、最も好ましくは少なくとも3つ:
・対照母集団に対して高速な毛髪及び爪の成長。
・同じ民族の人と比較して、より明るい色の肌及び眼を示す高い傾向。
・同じ民族の対照被験者よりも実質的に長いまつげ。
・色素脱失した皮膚の少なくとも5つの不連続領域。特に患者の背中に現れる。
・感染事象の期間、乳歯の喪失、外傷後傷害又は体温変化の内因性要因及び外因性要因の間における浮腫の徴候;より詳細には、眼窩周囲領域及び額領域に位置する顔面浮腫
・同じ年齢及び民族の定型発達者と比較した、γ−グルタミルトランスペプチダーゼ(GGT)の高い血中レベル。
・先天性泌尿生殖器系奇形及び/又は排尿開始機能障害。
・膝蓋骨の過形成。
・下痢の頻発。特に5歳より前。
・耳鳴りの頻発。
・脳梁の薄化。
・血液悪性腫瘍(特に、骨髄腫及び急性前骨髄球性白血病だが、これらに限定されない)の家族歴陽性。
・リウマチ性関節炎の家族歴陽性。すなわち、2世代続けて少なくとも2人の影響を受けた第一度近親者。
・アセチルサリチル酸又はその誘導体に応答する有害事象。
・虹彩欠損。片側又は両側のいずれか。
・睡眠多汗症。特に新生児、幼児及び小児(幼児期及び小児期における夜間発汗の著しい増加。ベッドリネンの交換が必要になると近親者より報告されることが多い)。
・Th1/Th2比の増加(すなわち、インターロイキン1β、インターロイキン6、TNF−α、インターフェロンγのレベル上昇)。
・先天性の副脾又は重複した脾臓。
・乳糜槽の先天性欠損。
・妊娠中にウイルス性又は細菌性感染症に罹患した母親及び/又は生物学的に確認された母親の妊娠中の免疫活性化の報告歴。
説明:上記のように特徴付けられた4人の患者に対して、イブジラストを投与した。4人の被験者は、軽度から重度まで様々なレベルの機能を有し、種々異なるレベルの言語能力及び知的能力を有していた。IQ値は、61〜86の範囲であった。全てが男性だった。
Claims (8)
- ・細胞内cAMPレベルを上昇させることができる物質、及び、
・細胞内カルシウム濃度を調節することができる物質
を含んでいる、ASD治療用の医薬組成物であって、
前記細胞内cAMPレベルを上昇させることができる物質が、PDE阻害剤であり、前記PDE阻害剤が、イブジラストであり、前記細胞内カルシウム濃度を調節することができる物質が、スルファモイル安息香酸4−置換誘導体である、医薬組成物。 - 前記スルファモイル安息香酸4−置換誘導体が、4−置換−3−アミノ−5−スルファモイル安息香酸誘導体である、請求項1に記載の医薬組成物。
- 前記4−置換−3−アミノ−5−スルファモイル安息香酸誘導体が、ブメタニド、AqB007、AqB011、PF−2178、BUM13、BUM5、ブメパミン及びそれらの混合物からなる群より選択される、請求項2に記載の医薬組成物。
- 前記細胞内cAMPレベルを上昇させることができる物質がイブジラストであり、前記細胞内カルシウム濃度を調節することができる物質がブメタニドである、請求項1に記載の医薬組成物。
- ・細胞内cAMPレベルを上昇させることができる物質、及び、
・細胞内カルシウム濃度を調節することができる物質
を含んでいる、ASD治療用のキットであって、
前記細胞内cAMPレベルを上昇させることができる物質が、PDE阻害剤であり、前記PDE阻害剤が、イブジラストであり、前記細胞内カルシウム濃度を調節することができる物質が、スルファモイル安息香酸4−置換誘導体である、キット。 - 前記スルファモイル安息香酸4−置換誘導体が、4−置換−3−アミノ−5−スルファモイル安息香酸誘導体である、請求項5に記載のキット。
- 前記スルファモイル安息香酸4−置換誘導体が、ブメタニド、AqB007、AqB011、PF−2178、BUM13、BUM5、ブメパミン及びそれらの混合物からなる群より選択される、請求項6に記載のキット。
- 前記細胞内cAMPレベルを上昇させることができる物質がイブジラストであり、前記細胞内カルシウム濃度を調節することができる物質がブメタニドである、請求項7に記載のキット。
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762582141P | 2017-11-06 | 2017-11-06 | |
US62/582,141 | 2017-11-06 | ||
EP17200219.8 | 2017-11-06 | ||
EP17200219 | 2017-11-06 | ||
US201862663647P | 2018-04-27 | 2018-04-27 | |
EP18169952.1 | 2018-04-27 | ||
US62/663,647 | 2018-04-27 | ||
EP18169952 | 2018-04-27 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018208833A Division JP2019089755A (ja) | 2017-11-06 | 2018-11-06 | 自閉症を治療するための医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020059711A true JP2020059711A (ja) | 2020-04-16 |
JP7012054B2 JP7012054B2 (ja) | 2022-02-10 |
Family
ID=64023965
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018208833A Pending JP2019089755A (ja) | 2017-11-06 | 2018-11-06 | 自閉症を治療するための医薬組成物 |
JP2019191270A Active JP7012054B2 (ja) | 2017-11-06 | 2019-10-18 | 自閉症を治療するための医薬組成物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018208833A Pending JP2019089755A (ja) | 2017-11-06 | 2018-11-06 | 自閉症を治療するための医薬組成物 |
Country Status (11)
Country | Link |
---|---|
US (3) | US10940140B2 (ja) |
EP (3) | EP3498297B1 (ja) |
JP (2) | JP2019089755A (ja) |
KR (1) | KR102372678B1 (ja) |
CN (1) | CN109821019A (ja) |
AU (1) | AU2018260807B2 (ja) |
BR (1) | BR102018072757A2 (ja) |
CA (1) | CA3023014C (ja) |
DK (1) | DK3785733T3 (ja) |
ES (2) | ES2908863T3 (ja) |
PL (1) | PL3785733T3 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3480597A1 (en) * | 2017-11-06 | 2019-05-08 | Stalicla S.A. | Biomarker assay for use in monitoring autism |
CA3023014C (en) * | 2017-11-06 | 2023-09-26 | Stalicla Sa | Pharmaceutical composition for treatment of autism |
GB201911603D0 (en) * | 2019-08-14 | 2019-09-25 | Healx Ltd | Treatment |
GB201912760D0 (en) * | 2019-09-05 | 2019-10-23 | Healx Ltd | Treatment |
US20210180130A1 (en) * | 2019-12-13 | 2021-06-17 | Seawire Consultoria e Comercio LDA | Detection and treatment of autism spectrum disorders |
EP3881842A1 (en) * | 2020-03-19 | 2021-09-22 | Stalicla S.A. | Compositions for the treatment of autism spectrum disorder |
CA3195170A1 (en) * | 2020-10-16 | 2022-04-21 | Georgios DRAKAKIS | Compositions and uses thereof |
EP4012414A1 (en) | 2020-12-11 | 2022-06-15 | Stalicla S.A. | Diagnosis of autism spectrum disorder phenotype 1 |
CN113528650B (zh) * | 2021-08-03 | 2022-03-08 | 长沙艾克曼生物科技有限公司 | Tmp21基因的表达可以作为自闭症早期筛查、早期识别和症状严重程度预测的客观指标 |
CN118434419A (zh) * | 2021-12-21 | 2024-08-02 | 国立大学法人大阪大学 | 类鸦片用于治疗自闭症谱系障碍的用途 |
WO2023198176A1 (en) * | 2022-04-15 | 2023-10-19 | Xinhua Hospital Affiliated To Shanghai Jiaotong University School Of Medicine | Prediction of the treatment response to bumetanide in subject with autism spectrum disorder |
CN114974571B (zh) * | 2022-05-27 | 2023-03-24 | 浙江大学医学院附属儿童医院 | 多模态数据驱动的孤独症检测系统、设备及存储介质 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006527177A (ja) * | 2003-06-06 | 2006-11-30 | ウニベルジテートスクリニクム フライブルク | 門脈圧亢進症の予防及び/又は治療のため薬剤又は医薬組成物 |
JP2013517251A (ja) * | 2010-01-15 | 2013-05-16 | インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) | 自閉症の治療のための化合物 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000020592A1 (en) * | 1998-10-07 | 2000-04-13 | Medical College Of Georgia Research Institute, Inc. | Glucose-dependent insulinotropic peptide for use as an osteotropic hormone |
US20050282896A1 (en) * | 2002-10-07 | 2005-12-22 | The University Of Alberta | Methods of cardioprotection using dichloroacetate in combination with an inotrope |
US20060034941A1 (en) * | 2002-12-23 | 2006-02-16 | Global Cardiac Solutions Pty Ltd | Organ preconditioning, arrest, protection, preservation and recovery |
EP2377530A3 (en) * | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
US20070299089A1 (en) * | 2006-06-22 | 2007-12-27 | Cv Therapeutics, Inc. | Use of A2A Adenosine Receptor Agonists in the Treatment of Ischemia |
WO2008019106A1 (en) * | 2006-08-04 | 2008-02-14 | Artesian Therapeutics, Inc. | Methods and compositions for the treatment of pulmonary hypertension using a combination of a calcium channel blocker and a phosphodiesterase inhibitor |
EP2389371A4 (en) * | 2009-01-22 | 2012-09-12 | Neurotherapeutics Pharma Inc | ANALOGUES OF BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE AND TORSEMID, AND RELATED COMPOSITIONS AND METHODS OF USE |
WO2011004166A1 (en) * | 2009-07-09 | 2011-01-13 | Cbt Development Limited | Combined preparation for use as a medicament |
WO2011112961A1 (en) * | 2010-03-12 | 2011-09-15 | Children's Medical Center Corporation | Methods and compositions for characterizing autism spectrum disorder based on gene expression patterns |
US10220008B2 (en) * | 2013-08-14 | 2019-03-05 | Stc.Unm | Treatment and prevention of stroke and other neurological disorders |
US9149457B2 (en) * | 2013-09-27 | 2015-10-06 | Justin SHER | Nutraceutical composition for PDE4 inhibition, enhanced dopamine metabolism and long term potentiation |
CA3023014C (en) * | 2017-11-06 | 2023-09-26 | Stalicla Sa | Pharmaceutical composition for treatment of autism |
-
2018
- 2018-11-01 CA CA3023014A patent/CA3023014C/en active Active
- 2018-11-05 BR BR102018072757-5A patent/BR102018072757A2/pt not_active IP Right Cessation
- 2018-11-06 CN CN201811313114.6A patent/CN109821019A/zh active Pending
- 2018-11-06 KR KR1020180134861A patent/KR102372678B1/ko active IP Right Grant
- 2018-11-06 AU AU2018260807A patent/AU2018260807B2/en active Active
- 2018-11-06 EP EP18204763.9A patent/EP3498297B1/en active Active
- 2018-11-06 DK DK20195373.4T patent/DK3785733T3/da active
- 2018-11-06 EP EP21208058.4A patent/EP3984555A1/en active Pending
- 2018-11-06 EP EP20195373.4A patent/EP3785733B1/en active Active
- 2018-11-06 ES ES20195373T patent/ES2908863T3/es active Active
- 2018-11-06 US US16/182,553 patent/US10940140B2/en active Active
- 2018-11-06 PL PL20195373T patent/PL3785733T3/pl unknown
- 2018-11-06 ES ES18204763T patent/ES2962383T3/es active Active
- 2018-11-06 JP JP2018208833A patent/JP2019089755A/ja active Pending
-
2019
- 2019-10-18 JP JP2019191270A patent/JP7012054B2/ja active Active
-
2020
- 2020-12-18 US US17/126,412 patent/US11439627B2/en active Active
-
2021
- 2021-01-29 US US17/162,118 patent/US20210154177A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006527177A (ja) * | 2003-06-06 | 2006-11-30 | ウニベルジテートスクリニクム フライブルク | 門脈圧亢進症の予防及び/又は治療のため薬剤又は医薬組成物 |
JP2013517251A (ja) * | 2010-01-15 | 2013-05-16 | インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) | 自閉症の治療のための化合物 |
Non-Patent Citations (3)
Title |
---|
ACS CHEMICAL NEUROSCIENCE, vol. 2016,7, JPN6019013411, 1 December 2015 (2015-12-01), pages 143 - 148, ISSN: 0004522656 * |
CELLULAR SIGNALLING, vol. 36, JPN6019013412, 21 April 2017 (2017-04-21), pages 14 - 24, ISSN: 0004522657 * |
RODGERS K.ET AL.: "Glial modulation with Ibdilast(MN166) attenuates neuroinflammation and autistic-like behaviors in th", PRESENTATION ABSTRACT, NEUROSCIENCE 2012[ONLINE](RETRIEVED ON 2019 MAR 14), JPN6019013410, 2012, ISSN: 0004522655 * |
Also Published As
Publication number | Publication date |
---|---|
EP3984555A1 (en) | 2022-04-20 |
CN109821019A (zh) | 2019-05-31 |
US11439627B2 (en) | 2022-09-13 |
KR102372678B1 (ko) | 2022-03-10 |
CA3023014A1 (en) | 2019-05-06 |
US20210145803A1 (en) | 2021-05-20 |
AU2018260807A1 (en) | 2019-05-23 |
EP3498297C0 (en) | 2023-06-21 |
US20190134011A1 (en) | 2019-05-09 |
ES2908863T3 (es) | 2022-05-04 |
KR20190051853A (ko) | 2019-05-15 |
JP7012054B2 (ja) | 2022-02-10 |
EP3785733A1 (en) | 2021-03-03 |
ES2962383T3 (es) | 2024-03-18 |
AU2018260807B2 (en) | 2020-07-09 |
EP3498297A1 (en) | 2019-06-19 |
JP2019089755A (ja) | 2019-06-13 |
DK3785733T3 (da) | 2022-04-11 |
EP3785733B1 (en) | 2022-01-05 |
US10940140B2 (en) | 2021-03-09 |
PL3785733T3 (pl) | 2022-07-11 |
EP3498297B1 (en) | 2023-06-21 |
CA3023014C (en) | 2023-09-26 |
US20210154177A1 (en) | 2021-05-27 |
BR102018072757A2 (pt) | 2019-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102372678B1 (ko) | 자폐증 치료를 위한 약제학적 조성물 | |
KR100881046B1 (ko) | 기분 장애를 치료하기 위한 카르보스티릴 유도체 및 기분안정화제 | |
US11234973B2 (en) | Use of pridopidine for the treatment of fragile X syndrome | |
Schmauss | An HDAC-dependent epigenetic mechanism that enhances the efficacy of the antidepressant drug fluoxetine | |
Coyle | Schizophrenia: basic and clinical | |
US20060217404A1 (en) | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | |
US20110008468A1 (en) | Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders | |
Malter et al. | Fragile X Syndrome and Alzheimer's Disease: Another story about APP and β-amyloid | |
US20230405017A1 (en) | Methods of using rho kinase inhibitors to treat frontotemporal dementia | |
Alquézar et al. | Targeting cyclin D3/CDK 6 activity for treatment of Parkinson's disease | |
Di Prisco et al. | Functional adaptation of presynaptic chemokine receptors in EAE mouse central nervous system | |
Onyameh | Central Nervous System (CNS) Multi-receptor Ligands for Schizophrenia | |
Caricati-Neto et al. | A new neuroprotective strategy for the drug therapy of Parkinson’s disease: signaling as therapeutic targets | |
Solanki et al. | Combined Treatment of Aripiprazole and Escitalopram Oxalate Therapy to Treat Major Depressive Disorders. | |
EP3441066A1 (en) | Application using mapk signal pathway inhibitor for preparing pharmaceutical product for delaying dopaminergic neuron degeneration | |
Zacher et al. | Iloperidone: Efficacy Review for the Acute Treatment of Schizophrenia in Adults. | |
Dolder et al. | Psychopharmacology: Pharmacodynamic Approach | |
Malter et al. | Fragile X Syndrome and Alzheimer's Disease: Another Story About APP and ß-Amyloid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200616 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210604 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210906 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211221 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220117 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7012054 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |